Skip to main content

Shearman & Sterling, Fangda Partners and Tian Yuan Law Firm have advised Chinese cancer cell therapy developer JW Therapeutics on its $300 million IPO in Hong Kong, with Davis Polk & Wardwell and Commerce & Finance Law Offices counselling the joint sponsors and underwriters.

JW Therapeutics is a clinical stage cell therapy platform company, founded by Juno Therapeutics and WuXi AppTec in 2016, and focused on developing, manufacturing and commercialising breakthrough cell-based immunotherapies for hematological cancers and solid tumours.

The listing is the latest in the recent flurry of biotech IPOs in Hong Kong. Other recent issuers in the city include Simcere Pharmaceutical Group, JHBP (CY) Holdings and Everest Medicines.

The Shearman team was led by partners Kyungwon (Won) Lee and Max Hua.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

Deals

N&A, S&C, TMI advise as Japan's Nidec makes $1.6 bln bid for Makino Milling

by Asian Legal Business《亚洲法律杂志》 |

TMI Associates, Freshfields and Davis Polk & Wardwell have represented Japanese manufacturing giant Nidec on its 257-billion-yen ($1.6 billion) bid for Makino Milling Machine, which turned to Nishimura & Asahi and Sullivan & Cromwell for advice.

Deals

N&A, MHM, Skadden, STB guide JX Advanced Metal’s $3 bln Japan IPO

by Nimitt Dixit |

Nishimura & Asahi and Skadden Arps Slate Meagher & Flom are advising JX Advanced Metals on its upcoming 460-billion-yen ($3 billion) initial public offering, the largest listing in Japan since SoftBank Corp’s $23.5 billion IPO in 2018.

Deals

Trilegal, Touchstone, CAM act on Carlyle’s $400 mln entry into India auto-components space

by Nimitt Dixit |

Trilegal has advised global private equity firm Carlyle on its acquisition of majority stakes in Highway Industries (HIL) and Roop Automotives for $400 million, marking its entry into India's auto components sector through a new manufacturing platform.